Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs).

Biotechnology

Tectonic Therapeutic

Alise Reicin

Daniel Lochner

Ashley Smith

Zachary MacBain

Ximena Barros-Álvarez

Victoria Jenny

Thomas McElrath

Othman Benchama

John Fernandez

Ian Pavelich, Ph.D.

Rebecca Smith

Xiaofei Li, PhD

Vasudha Sharma

Sarulatha Thulasi Raman

Sarah Nordeen

Peter Marek

Mounika Rao

Luke Turechek

Lindsay Clark

Katelyn Pyper

Joana Khatib

Jason Booe

Hitesh Soni, Ph.D., MBA

Emilie Ogisu

Arthur MARIVIN, PhD

Jaime Darce

Yao Fan

Rohit Anand

John Diener

Kathryn Bracken

Joseph Toth

Anthony (Tony) Muslin

Barry Rubenstein

Peter McNamara

Christian Cortis

Marc Schwabish

Anthony Muslin

The Research and Development team at Tectonic Therapeutic focuses on pioneering the discovery and development of antibodies and biologic drugs targeting G-protein Coupled Receptors (GPCRs). This team, composed of experts in cell biology, pharmacology, protein design, and antibody discovery, works collaboratively to advance innovative therapies, optimize protein design, and enhance drug efficacy for unmet medical needs.

Research and Development

Development and Program Management

Leadership Team

Research and Development

About

Team members

Other teams at Tectonic Therapeutic

Development and Program Management

Leadership Team